TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Hair-loss products in the UK grew 32% in the year to the end of August, according to Worldpanel by Numerator, as use of GLP-1 medicines also rose. A BMJ study reported an association between GLP-1 drugs and increased hair-loss risk, but researchers described the absolute risk as low; the cause and extent of any effect remain uncertain.
UK hair-loss product sales grew by 32% in the year to the end of August, according to Worldpanel by Numerator, as use of GLP-1 medicines rose and research examined a possible association with hair loss. The figures point to a growing market for products aimed at thinning and shedding, but do not establish that the medicines caused the sales increase or that every user faces the same risk.
Worldpanel by Numerator data cited by Cosmetics Business put the share of Great British households using GLP-1 medicines at 2.3% in 2024, rising to 4.1% in 2025 and 6.3% this year. The source describes the medicines as including semaglutide and tirzepatide, which are sold under brand names including Ozempic, Wegovy and Mounjaro. The figures are household usage estimates, not the percentage of individuals taking the drugs.
The report says products marketed for hair loss, thinning and strengthening have been part of hair care for years. What is changing, it argues, is demand: the rise in GLP-1 use is coinciding with greater interest in products addressing shedding. Worldpanel’s 32% figure measures sales growth over the year to the end of August; the source does not provide a sales value or a comparison with other product categories.
A study published in the British Medical Journal identified an association between GLP-1 medicines and increased risk of hair loss, according to the report. The researchers said the absolute risk was low. Cosmetics Business also reported that Novo Nordisk, maker of Ozempic, had announced an intention to enter the hair-loss treatment market. The source provides no product details, development timeline or evidence that a specific treatment is ready for use.
A New Demand Driver for Hair Care
The overlap between increased GLP-1 use, research on possible hair shedding and rising sales creates a commercial opportunity for hair-care companies. Brands may see demand for products positioned around thinning or hair strength, while drugmakers may explore treatments for concerns associated with their medicines. The reported sales growth is a market signal, not proof of why shoppers bought these products.
For people considering or taking GLP-1 medicines, the research may add a possible side effect to discussions with a health professional. The report stresses that the absolute risk is low; it does not show that hair loss is inevitable or that over-the-counter hair products prevent or treat drug-associated shedding. The distinction matters as commercial interest grows alongside scientific attention.
Popular right now
Roborock F25 GT Set Cordless Wet Dry Vacuum Cleaner and Mop with 2 Brushes
TCL T7 Series 85-Inch 4K 144Hz QLED Smart Google TV
Ninja Hot & Iced XL Coffee Maker with Rapid Cold Brew, Black, CM371
As an affiliate, we earn on qualifying purchases.
From Anecdotes to Published Research
Hair products that promise volume, thickness or stronger strands predate the current rise in GLP-1 medicines. The development described in the Cosmetics Business report is a shift in the factors thought to be driving demand, not the arrival of an entirely new category. Earlier accounts of shedding among people using these medicines were described as anecdotal; the BMJ study adds published research identifying an association.
The household figures show a steady increase across the three reported years: 2.3% in 2024, 4.1% in 2025 and 6.3% this year. The source does not give the precise survey dates or further methodology in the extract. It also does not report a direct study linking GLP-1 use to the 32% rise in hair-loss product sales, so the two trends should be treated as coinciding rather than as a demonstrated cause and effect.
“Hair loss products in the UK grew by 32% in the year to the end of August.”
— Cosmetics Business, citing Worldpanel by Numerator
Cause, Risk and Market Link
The source extract does not provide the BMJ study’s sample size, methods, specific risk estimates or details about how it assessed different medicines. It therefore is not possible from the supplied information to judge how the association varies by drug, dose, duration of use or patient characteristics. An association alone does not establish that a medicine directly caused hair loss.
The connection between rising GLP-1 use and the growth in hair-loss product sales is also not demonstrated in the reported figures. The source does not say how many buyers use these medicines, what prompted their purchases, or whether other factors contributed to the sales change. Novo Nordisk’s reported plans are similarly preliminary in the available material: no named product, evidence of effectiveness, regulatory status or launch date is supplied.
Research and Product Plans Ahead
Further study details and research would help clarify the size and nature of any hair-loss risk associated with GLP-1 medicines. In the meantime, people who notice shedding while taking a prescription medicine can raise it with their prescriber rather than assume the cause or stop treatment without advice.
For the market, the next developments to watch are whether Worldpanel reports continued sales growth and whether Novo Nordisk provides specifics about its stated interest in hair-loss treatments. Until more information is available, the reported figures show a coinciding rise in use and product sales, while the medical and commercial links remain only partly established.
Key Questions
Did GLP-1 medicines cause UK hair-loss product sales to rise?
The supplied report does not establish that. Worldpanel by Numerator reported 32% sales growth in the year to the end of August, while GLP-1 use was also rising. The figures show a coincidence, not a proven cause.
What did the BMJ study find about hair loss?
As summarized by Cosmetics Business, the study identified an association between GLP-1 medicines and increased hair-loss risk. Researchers described the absolute risk as low. The source extract does not include the study’s methods or detailed risk estimates.
How common was GLP-1 use in Great Britain?
Worldpanel by Numerator estimated that GLP-1 medicines were used by 2.3% of households in 2024, 4.1% in 2025 and 6.3% this year. These are household estimates, not individual usage rates.
Is Novo Nordisk launching a hair-loss treatment?
The report says Novo Nordisk announced an intention to enter the hair-loss treatment market. The available source does not identify a product or provide a launch date, clinical results or regulatory details.
Source: rss
